Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis ...Middle East

Medscape - News
In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting protective effects against acute anterior uveitis. Medscape Medical News

Hence then, the article about bimekizumab lowers uveitis rates in axial spondyloarthritis was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis )

Apple Storegoogle play

Last updated :

Also on site :